Applied DNA Sciences (NASDAQ:APDN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research report report published on Monday morning. The brokerage issued a hold rating on the technology company’s stock.

Separately, HC Wainwright decreased their price target on Applied DNA Sciences from $40.00 to $30.00 and set a buy rating for the company in a research note on Friday, February 9th.

Applied DNA Sciences Trading Up 0.8 %

Applied DNA Sciences stock opened at $4.03 on Monday. Applied DNA Sciences has a 12 month low of $3.60 and a 12 month high of $37.20. The business’s fifty day simple moving average is $8.60 and its two-hundred day simple moving average is $12.57. The company has a market capitalization of $3.43 million, a price-to-earnings ratio of -0.37 and a beta of 0.07.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Thursday, February 8th. The technology company reported ($1.80) earnings per share for the quarter, topping the consensus estimate of ($6.20) by $4.40. Applied DNA Sciences had a negative return on equity of 159.93% and a negative net margin of 80.14%. The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $0.70 million. On average, equities research analysts predict that Applied DNA Sciences will post -12.6 EPS for the current year.

Institutional Trading of Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned about 0.72% of Applied DNA Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). 22.22% of the stock is owned by hedge funds and other institutional investors.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.